This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million
by Zacks Equity Research
Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone
Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Las Vegas Sands (LVS), Phillips 66 (PSX) and AstraZeneca (AZN).
The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
by Zacks Equity Research
PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
by Kinjel Shah
Pipeline success, cost-cutting measures, share buybacks, product launches, ramped up M&A and collaboration activities should keep the sector afloat, going forward.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
AstraZeneca Up This Year on New Drugs & Pipeline Progress
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Top Research Reports for Merck, Adobe & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Adobe (ADBE) and Broadcom (AVGO).
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Here's Why Momentum Investors Will Love Astrazeneca (AZN)
by Zacks Equity Research
Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Britain Headed for a Soft Brexit? 5 Picks
by Swarup Gupta
Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.
Bayer Submits Application in EU for Prostate Cancer Drug
by Zacks Equity Research
Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
Should Value Investors Pick AstraZeneca PLC (AZN) Stock?
by Zacks Equity Research
Is AstraZeneca PLC (AZN) a great pick from the value investor's perspective right now? Read on to know more.
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
by Zacks Equity Research
J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression